---
layout: layouts/session.njk
permalink: /sessions/2026/03/index.html
title: "GLP-1 Receptor Agonists & Perioperative Aspiration Risk"
subtitle: "Examining the evidence: Do GLP-1 RAs increase aspiration pneumonia risk, and should we hold them before procedures?"
session_date: "March 2026"
breadcrumb: "Interactive Learning Module"
module_label: "CA2 Journal Club Module"

faculty:
  - "Dr. Artin Yeranossian"
  - "Dr. Gloria Belonwu"

resident_presenters:
  - "Dr. Nick Balardi"
  - "Dr. Ravina Brring"

categories:
  - Perioperative Medicine
  - Pharmacology
  - Evidence-Based Practice

central_question:
  text: "If GLP-1 receptor agonists delay gastric emptying, why do studies show conflicting results on aspiration pneumonia risk?"
  consideration: "Is delayed gastric emptying a clinically meaningful <em>cause</em> of aspiration, or merely a physiologic finding without proportionate clinical consequences?"

importance_heading: "Why This Matters to Anesthesiologists"

stats:
  - value: "6&ndash;15%"
    label: "US adults now prescribed GLP-1 RAs"
  - value: "4&ndash;5&times;"
    label: "Increase in GLP-1 RA prescriptions since 2020"
  - value: "0.6&ndash;0.8%"
    label: "Baseline aspiration pneumonia rate in surgical patients"

modifiable_factors:
  - Preoperative fasting duration
  - GLP-1 RA hold timing
  - Procedure type selection
  - Sedation depth/airway protection
  - Gastric ultrasound utilization

studies:
  - id: yeo
    title: "Yeo et al. (Gastroenterology 2024)"
    design: "Population-based retrospective cohort (TriNetX database)"
    badge: "Endoscopy Focus"
    badge_color: "red"
    results:
      - { label: "GLP-1RA Users", value: "0.83%" }
      - { label: "Non-Users", value: "0.63%" }
      - { label: "Hazard Ratio", value: "1.33" }
      - { label: "p-value", value: "0.036" }
    population: "n = 30,206 (matched) &middot; Age 21&ndash;70 &middot; Endoscopy 2018&ndash;2020"

  - id: chen
    title: "Chen et al. (JAMA Netw Open 2025)"
    design: "Retrospective cohort (MarketScan commercial claims)"
    badge: "Surgical Procedures"
    badge_color: "blue"
    results:
      - { label: "GLP-1RA Users", value: "0.7%" }
      - { label: "Non-Users", value: "0.6%" }
      - { label: "Odds Ratio", value: "0.78" }
      - { label: "p-value", value: "0.12" }
    population: "n = 366,476 &middot; Age &ge;18 &middot; 14 common surgeries &middot; 2020&ndash;2022"

comparison_table:
  heading: "Key Methodological Differences"
  columns:
    - Parameter
    - Yeo (Gastroenterology)
    - Chen (JAMA Netw Open)
  rows:
    - ["Database", "TriNetX (114M patients)", "MarketScan (273M patients)"]
    - ["Procedure Type", "Upper/lower endoscopy only", "14 common surgeries"]
    - ["GLP-1RA Definition", "&ge;6 months use + 2 refills", "Any Rx within 30 days"]
    - ["Study Period", "2018&ndash;2020 (pre-ASA guidance)", "2020&ndash;2022 (pre-ASA guidance)"]
    - ["Matching Variables", "59 covariates via PSM", "Multivariable logistic regression"]
    - ["Primary Finding", "HR 1.33 (p = 0.036)", "OR 0.78 (p = 0.12)"]
    - ["Propofol Subgroup", "HR 1.49 (p = 0.014)", "Not specifically analyzed"]
    - ["Upper GI Subgroup", "HR 1.48 (p = 0.018)", "Mixed procedures"]

reconciliation:
  heading: "Reconciling the Results"
  sections:
    - title: "Different Procedure Populations"
      cards:
        - label: "Yeo"
          text: "Endoscopy-specific: Upper airway manipulation, stomach insufflation, supine positioning &mdash; all increase aspiration opportunity"
        - label: "Chen"
          text: "Mixed surgical cohort: Many procedures (knee/hip arthroplasty, hernia repair) have inherently low aspiration risk regardless of gastric contents"

    - title: "Exposure Definition Differences"
      bullets:
        - "<strong>Yeo:</strong> Chronic users (&ge;6 months, 2 refills) &mdash; more likely true steady-state delayed gastric emptying"
        - "<strong>Chen:</strong> Any prescription within 30 days &mdash; includes new starts, may miss actual medication use"

    - title: "The Upper GI Hypothesis"
      text: "Yeo's subgroup analysis reveals the signal:"
      bullets:
        - "Upper endoscopy alone: HR 1.48 (p = 0.018)"
        - "Combined upper + lower: HR 2.26 (p = 0.007)"
        - "Colonoscopy alone: HR 0.56 (p = 0.16) &mdash; NO increased risk"
        - "Suggests stomach manipulation/insufflation is the key risk modifier"

    - title: "Propofol as Effect Modifier"
      text: "Yeo found <strong>propofol sedation</strong> amplified the risk signal:"
      cards:
        - label: "With Propofol"
          text: "HR 1.49 (95% CI 1.08&ndash;2.06, p = 0.014)"
          border: true
        - label: "Without Propofol"
          text: "HR 1.31 (95% CI 0.78&ndash;2.20, p = 0.31)"

    - title: "Absolute Risk Context"
      text: "Even with statistically significant findings, absolute risks remain low:"
      bullets:
        - "Yeo: 0.83% vs 0.63% = NNH ~500"
        - "Chen: 0.7% vs 0.6% = No significant difference"
        - "Clinical significance vs statistical significance"

deep_dives:
  - title: "Yeo et al. &mdash; Deep Dive"
    population:
      - "Age 21&ndash;70 years"
      - "Upper and/or lower endoscopy"
      - "January 2018 &ndash; December 2020"
      - "Excluded: Prior esophagectomy, gastrectomy, fundoplication"
      - "Excluded: Intubation/tracheostomy within 6 months"
    intervention: "GLP-1RA use &ge;6 months with &ge;2 refills within 6 months before procedure"
    comparator: "Never used GLP-1RA during study period"
    outcomes:
      - "<strong>Primary:</strong> Aspiration pneumonia within 30 days"
      - "Subgroups: Sex, propofol use, endoscopy type"
    key_results:
      - { value: "1.33", label: "Adjusted HR overall (p = 0.036)" }
      - { value: "1.49", label: "HR with propofol (p = 0.014)" }
      - { value: "2.26", label: "HR combined upper/lower (p = 0.007)" }
    strengths:
      - "Large matched cohort (15,000+ per group after PSM)"
      - "Rigorous 59-covariate propensity score matching"
      - "Pre-ASA guidance era (no hold contamination)"
      - "Clinically relevant subgroup analyses"
      - "Chronic user definition increases biological plausibility"
    limitations:
      - "Retrospective claims data &mdash; cannot confirm actual medication adherence"
      - "No data on fasting duration or gastric ultrasound"
      - "ICD-10 coding variability for aspiration pneumonia"
      - "Cannot distinguish aspiration pneumonitis vs pneumonia"
      - "No information on GLP-1RA hold timing"
      - "Three covariates with minor residual imbalance (SMD &lt;0.25)"

  - title: "Chen et al. &mdash; Deep Dive"
    population:
      - "Age &ge;18 years"
      - "14 common US surgical procedures"
      - "April 2020 &ndash; September 2022"
      - "Excluded: Multiple surgeries, pneumonia/resp failure within 90 days"
      - "Required: 90-day continuous insurance enrollment"
    intervention: "Any GLP-1RA prescription within 30 days before surgery (dulaglutide, exenatide, liraglutide, semaglutide)"
    comparator: "No GLP-1RA prescription"
    outcomes:
      - "<strong>Primary:</strong> 30-day aspiration pneumonia"
      - "<strong>Secondary:</strong> 90-day acute respiratory failure"
    null_result:
      text: "<strong>0.7% vs 0.6%</strong> aspiration pneumonia (GLP-1RA vs non-users). Despite higher baseline comorbidity burden in GLP-1RA users, no significant difference after adjustment."
      callout:
        label: "Robust Across Sensitivity Analyses"
        text: "Five sensitivity analyses (surgery type adjustment, anesthesia type, indication restriction, death exclusion, propensity score) all showed consistent null results"
    strengths:
      - "Large cohort (366,476 patients)"
      - "Nationwide commercial claims &mdash; multi-institutional"
      - "14 representative surgical procedures"
      - "Multiple sensitivity analyses"
      - "Pre-ASA guidance era"
      - "Adjusted for extensive comorbidities"
    limitations:
      - "Prescription &ne; actual medication use"
      - "30-day exposure window may miss chronic users"
      - "Heterogeneous surgical population dilutes signal"
      - "No Medicare patients (younger, healthier cohort)"
      - "No granularity on fasting, gastric ultrasound, case cancellations"
      - "Population-level surgical acuity categorization"

clinical_integration:
  heading: "Clinical Integration"
  sections:
    - title: "2023 ASA Consensus Guidance"
      text: "Hold GLP-1 RAs before elective procedures:"
      bullets:
        - "Daily dosing: Hold day of procedure"
        - "Weekly dosing: Hold 7 days before procedure"
        - "Consider proceeding if hold not feasible with full-stomach precautions"
        - "Consider gastric ultrasound if concerned"

    - title: "2024 Multisociety Guidance Update"
      text: "AGA/ASMBS/ASA/ISPCPO/SAGES joint statement:"
      bullets:
        - "Acknowledges limited evidence base"
        - "Individualized approach based on procedure type"
        - "GI symptoms (nausea, vomiting, bloating) may warrant longer hold"
        - "Shared decision-making emphasized"

    - title: "Practical Synthesis"
      cards:
        - label: "Higher Risk Procedures"
          text: "Upper endoscopy, EGD with propofol sedation, procedures with supine positioning and airway manipulation &mdash; consider holding GLP-1RA per ASA guidance"
          border: true
        - label: "Lower Risk Procedures"
          text: "Colonoscopy alone, extremity surgery, procedures with secure airway (ETT) &mdash; risk-benefit may favor continuing medication"
        - label: "Patient Factors"
          text: "GI symptoms, diabetes control implications of holding, procedure urgency all factor into individualized decision"

knowledge_check:
  - q: "What was the primary finding of the Yeo et al. (Gastroenterology 2024) study?"
    a: "GLP-1RA users had significantly higher aspiration pneumonia risk (HR 1.33, p = 0.036)"
  - q: "What was the primary finding of the Chen et al. (JAMA 2025) study?"
    a: "No significant difference in aspiration pneumonia (OR 0.78, p = 0.12)"
  - q: "In which procedure subgroup did Yeo et al. find the highest aspiration risk?"
    a: "Combined upper and lower endoscopy (HR 2.26, p = 0.007)"
  - q: "What was the effect of propofol sedation on aspiration risk in the Yeo study?"
    a: "Propofol amplified risk (HR 1.49, p = 0.014) vs no significance without propofol"
  - q: "How did the two studies define GLP-1RA exposure differently?"
    a: "Yeo required &ge;6 months use + 2 refills; Chen used any prescription within 30 days"
  - q: "What is the current ASA guidance for weekly GLP-1 RAs before elective surgery?"
    a: "Hold for 7 days before the procedure"
  - q: "Why might colonoscopy alone show no increased aspiration risk with GLP-1RAs?"
    a: "No upper airway manipulation or gastric insufflation; stomach contents less relevant"
  - q: "What is a key limitation shared by both studies?"
    a: "Neither could confirm actual medication adherence (prescription &ne; use)"
  - q: "What absolute aspiration pneumonia rates did both studies find?"
    a: "0.6&ndash;0.8% in both groups &mdash; low absolute risk regardless of GLP-1RA status"
  - q: "How should these findings influence clinical practice?"
    a: "Individualize based on procedure type (upper GI vs other), sedation plan, and patient symptoms; consider ASA guidance for high-risk scenarios"
---ru